Research programme: single domain antibody therapeutics - AdAlta

Drug Profile

Research programme: single domain antibody therapeutics - AdAlta

Alternative Names: AD 114; i-bodies

Latest Information Update: 10 Nov 2016

Price : $50

At a glance

  • Originator AdAlta
  • Developer AdAlta; Lonza
  • Class Antibodies; Antifibrotics; Proteins
  • Mechanism of Action G protein-coupled receptor modulators; Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Idiopathic pulmonary fibrosis
  • Research Fibrosis; Retinal disorders

Most Recent Events

  • 07 Nov 2016 AdAlta in-licenses PASylation® technology from XL-protein
  • 21 Sep 2016 Research programme: single domain antibody therapeutics - AdAlta is available for licensing as of 12 Aug 2016. www.adalta.com.au
  • 08 Jul 2016 Preclinical trials in Idiopathic pulmonary fibrosis in Australia (unspecified route) before July 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top